Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 2 » Issue 2

Chronic airflow limitation in developing countries: burden and priorities

Authors Nadia Aït-Khaled, Donald A Enarson, Salah Ottmani, Asma El Sony, Mai Eltigani, Ricardo Sepulveda

Published 15 July 2007 Volume 2007:2(2) Pages 141—150


Nadia Aït-Khaled1, Donald A Enarson1, Salah Ottmani2, Asma El Sony3, Mai Eltigani3, Ricardo Sepulveda4

1International Union Against Tuberculosis and Lung Diseases, Paris, France; 2World Health Organization, Geneva, Switzerland; 3Epidemiological Laboratory, Khartoum, Sudan; 4National Institute of Thoracic Diseases, Santiago, Chile

Abstract: Respiratory disease has never received priority in relation to its impact on health. Estimated DALYs lost in 2002 were 12% globally (similar for industrialized and developing countries). Chronic airflow limitation (due mainly to asthma and COPD) alone affects more than 100 million persons in the world and the majority of them live in developing countries. International guidelines for management of asthma (GINA) and COPD (GOLD) have been adopted and their cost-effectiveness demonstrated in industrialized countries. As resources are scarce in developing countries, adaptation of these guidelines using only essential drugs is required. It remains for governments to set priorities. To make these choices, a set of criteria have been proposed. It is vital that the results of scientific investigations are presented in these terms to facilitate their use by decision-makers. To respond to this emerging public health problem in developing countries, WHO has developed 2 initiatives: “Practical Approach to Lung Health (PAL)” and the Global Alliance Against Chronic Respiratory Diseases (GARD)”, and the International Union Against Tuberculosis and Lung Diseases (The Union) has launched a new initiative to increase affordability of essential asthma drugs for patients in developing countries termed the “Asthma Drug Facility” (ADF), which could facilitate the care of patients living in these parts of the world.

Keywords: air flow limitation, asthma, COPD, intervention, cost-effectiveness, developing countries

Download Article [PDF]